drugset / Trial / NCT06742502
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical study is to evaluate the efficacy and safety of sintilimab combined with rituximab followed by R-CHOP regimen in treatment-naïve patients with primary mediastinal diffuse large B-cell lymphoma. The main questions it aims to answer are: 1. Objective response rate of sintilimab combined with rituximab 2. Objective response rate after R-CHOP regimen
Timeline
- Start
- 2024-11-12
- Primary completion
- 2027-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Nintedanib | Small molecule | — | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Sintlimab | Monoclonal antibody | 200 mg | — |
| Subject | Vincristine | Small molecule | — | — |